Minocycline induces protective autophagy in vascular endothelial cells exposed to an in vitro model of ischemia/reperfusion-induced injury

WENBIN DONG, SHIGENG XIAO, MIN CHENG, XIAODI YE and GAOLI ZHENG

Institute of Materia Medica, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang 310013, P.R. China

Received September 3, 2015; Accepted October 23, 2015

DOI: 10.3892/br.2015.554

Abstract. Minocycline has been reported to exhibit advantageous effects on ischemic stroke; however, the precise mechanism of minocycline remains to be established. In the present study, human umbilical vein endothelial cells (HUVECs) were subjected to in vitro simulated ischemia/reperfusion conditions to determine the potential effect of minocycline-induced autophagy on HUVEC damage under oxygen-glucose deprivation/reperfusion (OGD/R). The study demonstrated that minocycline enhanced autophagy in a dose-dependent manner in HUVECs exposed to OGD/R, and only low-dose minocycline protected HUVECs from OGD/R-induced damage. Subsequently, 3-methyladenine (3-MA) was added into the culture media and the protective effect of minocycline was abolished. At the same time, it has been observed that simultaneous treatment with 3-MA also inhibited the autophagy activity induced by minocycline. This finding could suggest that autophagy induced by minocycline serves as one of the potential protective mechanism underlying the beneficial effects of minocycline on ischemic injury.

Introduction

Stroke is a major cause of morbidity and mortality in humans. Approximately 65-80% of all strokes are ischemic, which is caused by a blood clot that lodges in an artery and affects the brain blood supply (1). Historically, neuronal and astrocytic damage following ischemic stroke have been the focus of stroke research. In fact, vascular endothelial cell changes following a stroke are also important, as a stroke also affects microvessels. The neurovascular unit, which is comprised of neurons, astrocytes, endothelial cells, pericytes and extracellular matrix, has received significant attention in the field of stroke recently (2,3).

Within the neurovascular unit, endothelial cells are critical for the blood flow, oxygen delivery, glucose delivery and the regulation of cerebral microcirculation (4,5). Cerebral ischemia induces biochemical and cellular reactions in endothelial cells, such as increased reactive oxygen species production, induced inflammatory response and apoptosis (6). Endothelial cell damage following cerebral ischemia usually leads to disruption of the blood-brain barrier and dysregulation of vascular tone, which eventually causes exacerbation of the injury (7). Consequently, protecting endothelial cells is a beneficial method to alleviate brain damage following ischemic stroke.

Minocycline, a semi-synthetic tetracycline antibiotic, is of particular therapeutic interest for central nervous system (CNS) disorders, as it has a high oral bioavailability, excellent penetration into the brain and is well tolerated in humans (8). Its efficacy has been demonstrated to exert neuroprotective effects on ischemic stroke in animals and clinical trials through reduction of inflammation, suppression of free radical production and attenuation of apoptosis (8-10). Despite the significant advances of minocycline in the treatment of cerebral ischemia, more precise mechanisms of minocycline remain to be established.

Autophagy is a tightly regulated catabolic process that recycles proteins and organelles using lysosomal machinery (11). In the CNS, autophagy is further activated by various stressors, including ischemia, hypoxia, energy deprivation, neurotoxins and excitotoxic stimuli (12). Such induced autophagy is considered to provide neuroprotection (12). Otherwise, excessive autophagy can induce cellular dysfunction or cell death (13). In endothelial cells, autophagy acts predominantly as a pro-survival pathway, protecting the cells from cerebral ischemia (14,15). As mentioned previously, minocycline has been shown to promote therapeutic benefits in experimental stroke. In addition, minocycline is reported to trigger autophagy in C6 glioma cells (16). Thus, we speculated that the induction of autophagy may be a potential mechanism underlying the protective effects of minocycline against cerebral ischemia.

In the present study, human umbilical vein endothelial cells (HUVECs) were subjected to stimulated ischemia/reperfusion condition in vitro to determine the potential effect of minocycline-induced autophagy on endothelial cell damage under oxygen-glucose deprivation/reperfusion (OGD/R) (17). The present study demonstrated that endothelial cells initiate an autophagic survival response during OGD/R under minocycline
treatment. Therefore, minocycline effectively prevented OGD/R-evoked damage by induction of protective autophagy.

Materials and methods

Reagents. Minocycline (MC), 3-methyladenine (3-MA), monodansylcadaverine (MDC) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco's Modified Eagle's Medium and fetal bovine serum were purchased from Gibco (Thermo Fisher Scientific, Carlsbad, CA, USA).

Cell line and cell culture. Primary HUVECs were purchased from All Cells (Emeryville, CA, USA). Cells were cultured in complete HUVEC medium at 37˚C with 5% CO₂ in 25 cm² flasks.

OGD/R. The culture medium was replaced and washed with deoxygenated, glucose-free Hank's balanced salt solution, and subsequently the cultures were placed in an airtight experimental hypoxia chamber (Billups-Rothenberg, Inc., San Diego, CA, USA) containing a gas mixture comprising 95% N₂ and 5% CO₂. To mimic an ischemia/reperfusion condition in vitro, cell cultures were exposed to OGD for 3 h, and subsequently, cells were incubated for 24 h under a normal growth condition. Cells without OGD served as the controls.

Real-time cell analysis with the xCELLigence system. Non-invasive and label-free monitoring of cellular behavior was carried out in an E-plate using the xCELLigence system Real-Time Cell Analyzer (RTCA) (18). A dimensionless parameter termed cell index (CI), which is derived as a relative change in measured electrical impedance to represent cell status, was performed using the RTCA Software 1.2 (Roche, Penzberg, Germany). Background impedance of each well was determined using 100 µl complete HUVEC medium prior to seeding the cells, and subsequently the HUVECs were seeded and cultured at an initial density of 5,000 cells/well for 15 h before OGD/R.

Cell viability assay. Cell viability was measured using the MTT assay. Briefly, cells were rinsed twice with phosphate-buffered saline (PBS), and subsequently, the culture medium was replaced with serum-free medium and 10 µl MTT solution (5 mg/ml in PBS) per well. After 4 h of incubation at 37˚C, medium was removed and 100 µl dimethyl sulfoxide was added to dissolve the purple formazan product. Following this, the plates were continuously shaken at room temperature for 10 min using the BioTek Synergy 2 multi-mode microplate reader (BioTek, Winooski, VT, USA). The absorbance was subsequently measured at 570 nm.

Western blot analysis. HUVECs were washed twice with PBS and the protein was isolated with cell lysis buffer containing a protease inhibitor mixture (Beyotime, Jiangsu, China) for 20 min. Following this, the insoluble material was centrifuged at 15,000 x g for 15 min at 4˚C. Protein concentration was determined using a bicinchoninic acid protein assay kit (Beyotime). Samples containing equal amounts of protein (30 µg) were separated by SDS-polyacrylamide gels and transferred to polyvinylidene difluoride members. Non-specific binding was blocked by incubation in 20 mM Tris-buffer (pH 7.5) with 0.1% Tween-20 (TBST) containing 5% fat-free milk for 1 h at room temperature. The blots were incubated at 4˚C with the primary antibody against LC3 (1:1,500, rabbit polyclonal antibody; cat. no. sc-2775S; Cell Signaling Technology, Beverly, MA, USA), beclin 1 (1:2,000, rabbit polyclonal antibody; cat. no. sc-3738S; Cell Signaling Technology) and β-actin (1:2,000, rabbit monoclonal antibody; cat. no. sc-12620S; Cell Signaling Technology) diluted in TBST containing 5% fat-free milk. Subsequently, the blots were washed with TBST and incubated at room temperature for 1 h with an appropriate horseradish peroxidase-conjugated secondary antibody (1:2,000, cat. no. sc-7047S; Cell Signaling Technology). Following this, they were washed three times for 10 min each with TBST. The membrane was further developed using the chemiluminescence ECL kit (Beyotime). To evaluate the results of the western blot analysis, each band was quantified by densitometry using the gel analysis software. All the detected proteins were densitometrically analyzed and normalized to β-actin in order to control the equal amount of protein loading.

Statistical analysis. Differences between the groups were analyzed by one-way analysis of variance, means of two groups were compared using Student's t-test (paired, 2-tailed). P<0.05 was considered to indicate a statistically significant difference. All the data are expressed as mean ± standard deviation.

Results

Minocycline protects HUVECs from OGD/R-induced injury. HUVECs are highly sensitive to OGD/R. To confirm the protective effect of minocycline on OGD/R-induced injury, a real-time cell analysis was first conducted to assess the cell viability in all the treatment groups. Real-time cell viability measurement of HUVECs demonstrates that OGD/R exposure caused a rapid decrease of the CI compared to the control group. The cell viability was also evaluated by treatment with 1-100 µM minocycline during OGD/R. Treatment with 1 or 10 µM minocycline clearly suppressed a decrease in the CI induced by OGD/R. However, the CI of the 100 µM minocycline-treatment group decreased significantly compared to the OGD/R exposed group, indicating that 100 µM minocycline treatment aggravated cell damage (Fig. 1A). This finding was supported by the MTT
assay carried out in the E-Plate following completion of the real-time measurement (Fig. 1B).

Taken together, these results suggest that a low dose of minocycline attenuates OGD/R-induced damage, whereas a high dose of minocycline exacerbates the OGD/R injury.

Minocycline induces autophagy in HUVECs exposed to OGD/R. As autophagy has been previously shown to be protective for several cell types, including HUVECs under OGD/R conditions, we speculated that autophagy induced by minocycline could be a mechanism of protection following OGD/R. To confirm this hypothesis, we investigated the expression of proteins considered as reliable autophagy markers to assess the status of autophagy in HUVECs exposed to OGD/R. Following the treatment, the levels of LC3 and beclin 1 were determined by western blot analysis at various concentrations of minocycline (1-100 µM).

LC3 and beclin 1 are the main autophagy markers (19). LC3 is associated with the autophagosomal membranes that exist in two molecular forms: LC3-I (18 kDa) and LC3-II (16 kDa). The cytoplasmic LC3-I form is converted into the lipidated LC3-II form, which is recruited to autophagosomal membranes during autophagy activation. The level of LC3-II is closely correlated with the number of autophagosomes, so it is considered as a common marker of autophagosome formation in mammalian cells. Beclin 1 is one component of a protein complex with PI3K, which has an important role in membrane trafficking and restructuring involved in the formation of autophagosomes.

As shown in Fig. 2, the OGD/R exposure significantly induced conversion of LC3-I to LC3-II and upregulated beclin 1 expression compared to the normal control group. The LC3-II and beclin 1 levels in HUVECs exposed to OGD/R was significantly increased following treatment with minocycline in a dose-dependent manner. These results indicate that minocycline triggers autophagy in the OGD/R-injured HUVEC.

Minocycline induces autophagy in HUVECs exposed to OGD/R. As autophagy has been previously shown to be protective for several cell types, including HUVECs under OGD/R conditions, we speculated that autophagy induced by minocycline could be a mechanism of protection following OGD/R. To confirm this hypothesis, we investigated the expression of proteins considered as reliable autophagy markers to assess the status of autophagy in HUVECs exposed to OGD/R. Following the treatment, the levels of LC3 and beclin 1 were determined by western blot analysis at various concentrations of minocycline (1-100 µM).

LC3 and beclin 1 are the main autophagy markers (19). LC3 is associated with the autophagosomal membranes that exist in two molecular forms: LC3-I (18 kDa) and LC3-II (16 kDa). The cytoplasmic LC3-I form is converted into the lipidated LC3-II form, which is recruited to autophagosomal membranes during autophagy activation. The level of LC3-II is closely correlated with the number of autophagosomes, so it is considered as a common marker of autophagosome formation in mammalian cells. Beclin 1 is one component of a protein complex with PI3K, which has an important role in membrane trafficking and restructuring involved in the formation of autophagosomes.

As shown in Fig. 2, the OGD/R exposure significantly induced conversion of LC3-I to LC3-II and upregulated beclin 1 expression compared to the normal control group. The LC3-II and beclin 1 levels in HUVECs exposed to OGD/R was significantly increased following treatment with minocycline in a dose-dependent manner. These results indicate that minocycline triggers autophagy in the OGD/R-injured HUVEC.

Protective effect of minocycline against OGD/R-induced injury in HUVECs is attenuated through induction of autophagy. To investigate the role of minocycline-induced autophagy in HUVECs exposed to OGD/R, the cells were treated with minocycline in the presence or absence of autophagy specific inhibitor 3-MA during OGD/R. 3-MA has been shown to effectively inhibit autophagy by blocking autophagosome formation via suppressing PI3K (19).

The effect of 3-MA on the neuroprotective effect of minocycline was analyzed by real-time cell analysis. The data shows that exposure of HUVECs to OGD/R led to a
significant decrease in cell viability, and treatment with minocycline significantly increased the cell viability indicating that the drug exerts a cytoprotective effect (Fig. 3A). At the same time, simultaneous addition of minocycline with 3-MA partly attenuated the protective effect of minocycline exerted on HUVECs with OGD/R exposure.

Subsequently, the expression of LC3 and beclin 1 was analyzed in all groups. As shown in Fig. 3B, OGD/R resulted in a significant increase of LC3-II and beclin 1 expression as compared with the control group, and minocycline-induced autophagy was indicated by higher LC3-II and beclin 1 levels following OGD/R. The addition of 3-MA suppressed the minocycline-induced autophagy, which was characterized by the reduction of LC3-II and beclin 1 in comparison with the minocycline group.

The autophagosome formation was further observed by staining HUVECs with MDC, a fluorescent dye that selectively incorporates into autophagolysosomes. The MDC-positive cells were markedly increased following subjection to OGD/R in comparison with the control group (Fig. 3C), and a significant increase in the number of MDC-labeled vesicles was observed in the minocycline group compared with the untreated cells. The addition of 3-MA effectively attenuated the accumulation of MDC-labeled fluorescent particles induced by minocycline. Taken together, these results suggest that induction of autophagy may partially explain the protective mechanism of minocycline against OGD/R-induced injury.

Discussion

Minocycline has beneficial effects on cerebral ischemia/reperfusion injury, accounting for its anti-inflammatory, antioxidant and anti-apoptotic properties. Although activation of autophagy may represent a cellular defense against oxidative stress, inflammation and apoptosis, the role of autophagy in the treatment of cerebral ischemia/reperfusion injury with minocycline remains to be elucidated. To the best of our knowledge, this is the first study to prove that minocycline was able to protect...
OGD/R-treated HUVECs in vitro by inducing autophagy. Autophagy is a dynamic and accurately regulated process of degradation and recycling of cellular components, and is involved in organelle turnover and in nutrient supply to maintain homeostasis and survival under starvation (20). In previous studies, it has been repeatedly demonstrated that impaired autophagy can cause neurodegenerative diseases (21,22). Increasing data have also revealed that activation of autophagy may contribute to neuroprotection in experimental models of cerebral ischemia in vivo and in vitro (23,24). The present data showed that minocycline can induce a beneficial autophagic process to protect the vascular endothelial cells in a model of ischemia/reperfusion injury in vitro.

Based on the model of OGD/R injury, using HUVECs treated with minocycline over 24 h, minocycline-enhanced autophagy was demonstrated to be in a dose-dependent manner in OGD/R-treated HUVECs. However, only a low dose of minocycline had a protective effect, while a high dose of minocycline exacerbates the OGD/R injury, which was consistent with a study reporting that moderate autophagy acts to promote cell survival whereas excessive levels of autophagy contribute to cell death (25).

To further confirm the role of autophagy in the protective effect of minocycline against OGD/R-induced injury, 3-MA, an autophagy inhibitor, was added into the culture media and the protective effect of minocycline was abolished. At the same time it was observed that simultaneous treatment with 3-MA also inhibited the autophagy activity induced by minocycline. This result demonstrates that moderate autophagy induced by minocycline could be a potential mechanism to understand the beneficial effects of minocycline on ischemic injury.

To the best of our knowledge, this is the first demonstration that autophagy serves as a protective mechanism of minocycline in ischemia-treated endothelial cells in vitro. This result suggests that the activation of autophagy may be a novel strategy for cerebral ischemia injury.

Acknowledgements

The present study was supported by grants from the Zhejiang Province Medical and Health Science and Technology Project (no. 2012ZDA009), the Key Medical Subjects Construction Project of Zhejiang (no. XKQ-010-001) and the National Major Scientific and Technological Special Project for ‘Significant New Drugs Development’ during the Twelfth Five-year Plan Period (no. 2013ZX09303005).

References

1. Lo EH: A new penumbra: Transitioning from injury into repair after stroke. Nat Med 14: 497-500, 2008.
2. Lee SR, Wang X, Tsuji K and Lo EH: Extracellular proteolytic pathophysiology in the neurovascular unit after stroke. Neuron Res 26: 854-861, 2004.
3. Moroni F and Chiarugi A: Post-ischemic brain damage: Targeting PARP-1 within the ischemic neurovascular units as a realistic avenue to stroke treatment. FEBS J 276: 36-45, 2009.
4. Curin Y, Ritz MF and Andriantsitohaina R: Cellular mechanisms of the protective effect of polyphenols on the neurovascular unit in strokes. Cardiovasc Hematol Agents Med Chem 4: 277-288, 2006.
5. Xie R, Li X, Ling Y, Shen C, Wu X, Xu W and Gao X: Alpha-lipoic acid pre- and post-treatments provide protection against in vitro ischemia-reperfusion injury in cerebral endothelial cells via Akt/mTOR signaling. Brain Res 1482: 81-90, 2012.
6. Olmez I and Ozyurt H: Reactive oxygen species and ischemic cerebrovascular disease. Neurochem Int 60: 208-212, 2012.
7. Sandoval KE and Witt KA: Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis 32: 200-219, 2008.
8. Buller KM, Carty ML, Reinebrant HE and Wixey JA: Minocycline: A neuroprotective agent for hypoxic-ischemic brain injury in the neonate. J Neurosci Res 87: 599-608, 2009.
9. Stirling DP, Koochesfahani KM, Steeves JD and Tetzlaff W: Minocycline as a neuroprotective agent. Neuroscientist 11: 308-322, 2005.
10. Switzer JA, Hess DC, Ergul A, Waller JL, Machado LS, Portik-Dobos V, Pettigrew LC, Clark WM and Fagan SC: Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. Stroke 42: 2633-2635, 2011.
11. Mizushima N, Levine B, Cuervo AM and Klionsky DJ: Autophagy fights disease through cellular self-digestion. Nature 451: 1069-1075, 2008.
12. Gabryel B, Kost A and Kasprowska D: Neuronal autophagy in cerebral ischemia—a potential target for neuroprotective strategies. Pharmacol Rep 64: 1-15, 2012.
13. Rami A, Langhagen A and Steiger S: Focal cerebral ischemia induces upregulation of Beclin 1 and autophagy-like cell death. Neurobiol Dis 29: 132-141, 2008.
14. Urbanek T, Kuczmik W, Bastia-Kaian A and Gabryel B: Rapamycin induces of protective autophagy in vascular endothelial cells exposed to oxygen-glucose deprivation. Brain Res 1553: 1-11, 2014.
15. Han J, Pan XY, Xu Y, Xiao Y, An Y, Tie L, Pan Y and Li XJ: Curcumin induces autophagy to protect vascular endothelial cell survival from oxidative stress damage. Autophagy 8: 812-823, 2012.
16. Liu WT, Lin CH, Hsiao M and Gean PW: Minocycline inhibits the growth of glioma by inducing autophagy. Autophagy 7: 166-175, 2011.
17. Ma X, Zhang H, Pan Q, Zhao Y, Chen J, Zhao B and Chen Y: Hypoxia/Acrycemia-induced endothelial barrier dysfunction and tight junction protein downregulation can be ameliorated by citicoline. PLoS One 8: e82604, 2013.
18. Liberio MS, Sadowski MC, Nelson CC and Davis RA: Identification of eusynustelamide B as a potent cell cycle inhibitor following the generation and screening of an ascidian-derived extract library using a real time cell analyzer. Mar Drugs 12: 5222-5239, 2014.
19. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnell M, Agostinis P, Aguirre-Ghiso JA, et al: Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8: 445-544, 2012.
20. Carloni S, Buonocore G and Balduini W: Protective role of autophagy in neonatal hypoxia-ischemia induced brain injury. Neurobiol Dis 32: 329-339, 2008.
21. Arizraei M, Kembell CC and Whiton JL: Autophagy, inflammation and neurodegenerative disease. Eur J Neurosci 33: 197-204, 2011.
22. Ferguson CJ, Lenk GM and Meisler MH: Defective autophagy in neurons and astrocytes from mice deficient in PI(3,5)P2. Hum Mol Genet 18: 4868-4878, 2009.
23. Adhami F, Schloemer A and Kuan CY: The roles of autophagy in cerebral ischemia. Autophagy 3: 42-44, 2007.
24. Zhang X, Yan H, Yuan Y, Gao J, Shen Z, Cheng Y, Shen Y, Wang RR, Wang X, Hu WW, et al: Cerebral ischemia-reperfusion-induced autophagy protects against neuronal injury by mitochondrial clearance. Autophagy 9: 1321-1333, 2013.
25. Wei K, Wang P and Miao CY: A double-edged sword with therapeutic potential: An updated role of autophagy in ischemic cerebral injury. CNS Neurosci Ther 18: 879-886, 2012.